MARKET

JBIO

JBIO

Jade Biosciences Inc
NASDAQ
22.43
+0.32
+1.45%
Opening 14:27 06/30 EDT
OPEN
22.08
PREV CLOSE
22.11
HIGH
23.09
LOW
21.50
VOLUME
461.40K
TURNOVER
--
52 WEEK HIGH
28.00
52 WEEK LOW
6.67
MARKET CAP
1.33B
P/E (TTM)
-9.2897
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at JBIO last week (0622-0626)?
Weekly Report · 1d ago
Jade Biosciences director Mark Eisner files initial beneficial ownership statement
PUBT · 3d ago
Jade Biosciences Appoints Mark Eisner To The Board Of Directors
NASDAQ · 4d ago
Jade Biosciences Adds Veteran Biopharma Leader to Board
TipRanks · 4d ago
Jade Biosciences names Vir Biotech ex-CMO Mark Eisner to board
PUBT · 4d ago
JADE BIOSCIENCES ANNOUNCES APPOINTMENT OF MARK EISNER, M.D., M.P.H., TO BOARD OF DIRECTORS
Reuters · 4d ago
Press Release: Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
Dow Jones · 4d ago
Top Biotech Gainers: BOLD Begins Anew, MNPR NDA Filing On Track, GALT Soars On FDA Alignment
NASDAQ · 6d ago
More
About JBIO
Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.

Webull offers Jade Biosciences Inc stock information, including NASDAQ: JBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JBIO stock methods without spending real money on the virtual paper trading platform.